CIP2A Antibody

CIP2A (cancerous inhibitor of PP2A) was originally identified as p90, a cytoplasmic autoantigen found in the serum from a cancer patient. It was later described as a protein that interacted with the c-myc oncogene and functioned as an inhibitor of protein phosphatase 2A (PP2A) activity. Inhibition of PP2A phosphatase activity by CIP2A prevents c-myc phosphorylation and counteracts c-myc proteolytic degradation, thereby stabilizing c-myc and promoting cell growth and transformation. CIP2A is found to be over expressed in some human malignancies and is thus classified as an oncogene that may be an important contributor to tumor formation.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 3 applications: IF/IHC, IHC-P, WB.

Showing Publications 1 - 10 of 11. Show All 11 Publications. Collapse Publications.

Publications using NB100-68264	Applications	Species
Miller RA Long-lived mice with reduced growth hormone signaling have a constitutive upregulation of hepatic chaperone-mediated autophagy Autophagy 2020-02-12 [PMID: 32013718] (WB, Mouse) Details: Snell dwarf mice	WB	Mouse
Tian Y, Chen H, Qiao L et al. CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells J. Cell. Mol. Med. 2018-06-12 [PMID: 29893470] (WB, Human)	WB	Human
Zhang W, Chen H, Chen Y et al. Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1. Oncotarget 2015-03-10 [PMID: 25650660] (WB)	WB
Guo Z, Liu D, Su Z. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway Tumor Biology. 2015-01-06 [PMID: 25560487] (WB, IHC-P, Human)	WB, IHC-P	Human
Wu Y, Gu TT, Zheng PS. CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression. Cancer Lett 2015-01-28 [PMID: 25458953]
Wang J, Huang T, Sun J et al. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus. Med. Oncol. 2014-08-01 [PMID: 25023053] (WB, Human) Details: CIP2A antibody used for WB in human samples. Fig. 1B shows the blot of CIP2A expression in bone marrow mononuclear cells from CML-CP patients (lanes 1-7) and healthy control (lane C). Fig. 2A and Fig 3A/B shows the CIP2A blots from K562 cells transfected CIP2A-specific or control siRNA. Fig 3C shows its levels in cells treated with CIP2A expression plasmid.	WB	Human
Johnson Mahlon D, Reeder Jay E, O'Connell Mary et al. CIP2A and PP2A in human leptomeninges, arachnoid granulations and meningiomas. J Clin Neurosci. 2014-07-08 [PMID: 25012485] (Human)		Human
Kim JS, Kim EJ, Oh JS, Park IC, Hwang SG. CIP2A modulates cell cycle progression in human cancer cells by regulating the stability and activity of PLK1. Cancer Res. 2013-08-27 [PMID: 23983103] (IF/IHC, Human)	IF/IHC	Human
Xue Y, Wu G, Wang X et al. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma Med Oncol 2013-03-01 [PMID: 23275123] (IF/IHC, WB, Human)	IF/IHC, WB	Human
Pallai R, Bhaskar A, Sodi V et al. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription. 2012-11-01 [PMID: 23117818]
Cristobal I, Garcia-Orti L, Cirauqui C et al. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect Leukemia 2011-04-01 [PMID: 21233840] (WB, Human)	WB	Human
Show All 11 Publications. Collapse Publications.

Array NB100-68264

• CIP2A Antibodies
• CIP2A ELISA Kits
• CIP2A Lysate
• CIP2A Protein